Skip to main content
Fig. 1 | Acta Neuropathologica Communications

Fig. 1

From: Targeting the A3 adenosine receptor to prevent and reverse chemotherapy-induced neurotoxicities in mice

Fig. 1

Prevention of cisplatin-induced cognitive deficits by the A3AR agonist MRS5980. a Male and female mice were treated with PBS or cisplatin (2 rounds of 5 daily doses of 2.3 mg/kg i.p. with 5 days of rest in between). MRS5980 was given daily (0.3 mg/kg/day i.p.), starting one day before cisplatin administration until one day after the last cisplatin injection. Behavioral tests were started 2 weeks after the last dose of cisplatin in the order listed and tissue was collected for immunostaining after completion of all tests. b Influence of MRS5980 on cisplatin-induced deficits in executive function as assessed using the puzzle box test (PBT). Data are presented as mean of time (s) used in the hard trials in which mice have to remove a plug blocking the tunnel to the dark compartment in order to escape from the light compartment. c Effect of cisplatin and MRS5980 on working memory in the novel object place recognition test (NOPRT). Preference for the novel object in the NOPRT is presented as discrimination index (DI: (Tnovel—Tfamiliar)/ (Tnovel + Tfamiliar). d Influence of cisplatin and MRS5980 on spatial memory in the Y-maze expressed as a percentage of perfect alternations in the Y-maze. Male (black circle; n = 7–8/group) and female (grey circle; n = 6–8/group) mice. Results are expressed as mean ± SEM; Two-way ANOVA with Tukey's post-hoc analysis **p ≤ 0.01; ***p ≤ 0.001; ****p ≤ 0.0001. No significant sex effects were detected

Back to article page